argenx SE (NASDAQ:ARGX) Shares Purchased by Cerity Partners LLC

Cerity Partners LLC lifted its stake in argenx SE (NASDAQ:ARGX) by 20.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,273 shares of the company’s stock after acquiring an additional 555 shares during the quarter. Cerity Partners LLC’s holdings in argenx were worth $1,774,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Raymond James Trust N.A. raised its position in shares of argenx by 6.0% during the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock worth $268,000 after acquiring an additional 28 shares in the last quarter. Valence8 US LP purchased a new position in argenx during the 3rd quarter worth $517,000. Charles Schwab Investment Management Inc. lifted its position in argenx by 28.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company’s stock valued at $1,875,000 after purchasing an additional 768 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of argenx by 15.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 927 shares of the company’s stock valued at $503,000 after buying an additional 123 shares during the period. Finally, Jennison Associates LLC boosted its stake in shares of argenx by 0.6% in the third quarter. Jennison Associates LLC now owns 237,966 shares of the company’s stock valued at $128,997,000 after buying an additional 1,528 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ARGX. JMP Securities lifted their price target on shares of argenx from $497.00 to $606.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company lifted their price target on shares of argenx from $547.00 to $639.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Raymond James reiterated a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a research note on Thursday, October 10th. Finally, Guggenheim lifted their price target on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and an average target price of $630.42.

argenx Trading Up 0.2 %

NASDAQ:ARGX opened at $617.49 on Tuesday. argenx SE has a 1-year low of $327.73 and a 1-year high of $622.32. The stock has a market cap of $37.28 billion, a P/E ratio of -701.69 and a beta of 0.61. The stock’s 50-day moving average is $565.73 and its 200-day moving average is $498.07.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period last year, the company earned ($1.25) earnings per share. As a group, equities analysts forecast that argenx SE will post 2.2 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.